Radioprotection by the histone deacetylase inhibitor phenylbutyrate
- 3 September 2011
- journal article
- research article
- Published by Springer Nature in Radiation and Environmental Biophysics
- Vol. 50 (4) , 585-596
Abstract
The histone deacetylase inhibitor (HDAC), phenylbutyrate (PB), is a novel anti-tumor agent. Studies have demonstrated that HDAC inhibitors can suppress cutaneous radiation syndrome and stimulate hematopoiesis. The objective of this study was to test the ability of PB treatment to protect against acute gamma-radiation-induced lethality in the DBA/2 mouse model. A 30-day radiation lethality study was used to assess radioprotective capability of PB. Mechanisms were evaluated using western blots, flow cytometry, and the single-cell gel electrophoresis assay. Western blot studies showed that PB treatment acetylated histones in vivo. For radiation protection studies, prophylactic administration of PB (24 h preradiation; 1–50 mg/kg) provided radioprotection against gamma radiation (8–9.5 Gy) and PB demonstrated a DRF of 1.31 (P = 0.001; 95% confidence interval: 1.27, 1.36). When PB (10 mg/kg) was administered post-radiation (4 h), it also provided significant radioprotection at 8.0 Gy radiation (P = 0.022). PB treatment before radiation was associated with significant elevations in neutrophils and platelets following radiation. Results from single-cell gel electrophoresis of peripheral blood leukocytes demonstrated that PB treatment before radiation can attenuate DNA damage and inhibit radiation-induced apoptosis. These results indicate that an HDAC inhibitor like PB has potential as a radiation protector and that mechanisms of action include attenuation of DNA damage and inhibition of apoptosis.Keywords
This publication has 44 references indexed in Scilit:
- The NIAID Radiation Countermeasures Program Business ModelBiosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science, 2010
- Alpha-tocopherol succinate protects mice from gamma-radiation by induction of granulocyte-colony stimulating factorInternational Journal of Radiation Biology, 2010
- Histone Deacetylase Inhibitors Protect against and Mitigate the Lethality of Total-Body Irradiation in MiceRadiation Research, 2008
- Pravastatin Inhibits the Rho/CCN2/Extracellular Matrix Cascade in Human Fibrosis Explants and Improves Radiation-Induced Intestinal Fibrosis in RatsClinical Cancer Research, 2007
- Simvastatin Ameliorates Radiation Enteropathy Development After Localized, Fractionated Irradiation by a Protein C-Independent MechanismInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Effect of Valproic Acid, a Histone Deacetylase Inhibitor, on Cell Death and Molecular Changes Caused by Low-Dose IrradiationAnnals of the New York Academy of Sciences, 2006
- RADIATION PROTECTANTS: CURRENT STATUS AND FUTURE PROSPECTSHealth Physics, 2005
- Histone deacetylase inhibitors are potent radiation protectantsCancer Biology & Therapy, 2004
- Modulation of radiation response of human tumour cells by the differentiation inducers, phenylacetate and phenylbutyrateInternational Journal of Radiation Biology, 1997
- Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate.Journal of Clinical Investigation, 1993